NEWSWIRE


“With 2 of every 3 American adults overweight and more than 4 in 10 of them obese, this is a potential cause for concern,” said Tracey caughlin, D, professor of endocrinology. Read on: https://www.hpnonline.com/21282917


FDA updates COVID-19 test policy The U.S. Food and Drug Administration updated its COVID-19 test policy to ensure continued access to tests while encouraging the transition of these important public health tools to traditional premarket review pathways. The updated policy describes the FDA’s intent to review only a small subset of new emergency use authorization (EUA) requests for diagnostic tests and encourages developers of all test types interested in marketing authoriza- tion to pursue authorization through the de novo classification or 510(k) clearance pre-market review pathways. “Testing remains one of the key pillars in combatting the CD- pandemic, said eff huren, .D., .D., director of the FDA’s Center for Devices and Radiological Health. “Taking into account the current status of manufacturing capacity and consumer access given the Administration’s important invest- ments in tests, for most new tests, shifting to traditional pre- market review would best meet the public health needs at the current stage of the COVID-19 public health emergency. The FDA will continue to offer support and expertise to assist with the development of accurate and reliable tests, and to facilitate continued access to tests for all Americans.” Since the start of the pandemic, the FDA has adapted its regu- latory approach to address the public’s testing needs and has worked closely with test developers to adjust as those needs have changed. These efforts have helped increase testing capacity and


broaden public access to rapid tests, including those purchased over-the-counter (OTC). The U.S. currently has the capacity for authorized manufacturers to produce hundreds of millions of tests per month, although the number of tests available for use at any given time will depend on demand and other factors. To date, more than 430 distinct COVID-19 tests have been issued EUAs. The available information indicates that these tests are providing sufficient testing capacity for CD- tests throughout the United States. Recognizing the current testing capacity, at this time, the agency believes most future submissions are best suited for traditional premarket review pathways. Therefore, the FDA is revising its policy to update the types of COVID-19 tests for which the agency intends to review EUA requests and discuss the use of the traditional premarket review pathways for COVID-19 tests. Tests for which EUA authorization requests are pending prior to this announcement will remain in the queue. Read on: https://www.hpnonline.com/21282103


Changes at the top for GHX


Global Healthcare Exchange (GHX) has announced that Bruce Johnson will transition from his role as president and Chief Executive fficer to Executive Chairman of the Board effective January 1, 2023. The H Board has confirmed Tina atanka urphy, division president, Value Based Care, to be appointed as the company’s next president and CEO.


+DYH \RX FKHFNHG \RXU LQVWUXPHQW LQVXODWLRQ ODWHO\"


7KH 2ULJLQDO 3RUWDEOH %DWWHU\ RSHUDWHG ,QVXODWLRQ &RQWLQXLW\ 7HVWHU ,QWURGXFLQJ


7KH WK *HQHUDWLRQ ,QVXODWLRQ 7HVWHU ZLWK )RRWFRQWURO


<RXU 3RUWDEOH ,QVXODWLRQ &RQWLQXLW\ 7HVWLQJ 'HYLFH


0LFURFRQWUROOHU 'ULYHQ &RPSOHWHO\ 5HXVDEOH $FFHVVRULHV


Johnson joined GHX when the company was founded in 2000 with a passion for creating something that had never existed in healthcare: an industry-unifying exchange platform led by a group of healthcare providers, suppliers and distributors working together to reduce the cost of delivering care. His suc- cessful tenure has resulted in a community of more than 896,000 trading partners including hospitals representing more than 90% of net patient revenue and suppliers representing 85% of medical-surgical spend in the U.S. Under Johnson’s leadership, GHX has delivered innovative solutions that have helped the healthcare community save more than $13.7 billion since 2010. “Serving as president and CEO of GHX for the last 15 years


$7, $)&


)RU YHULI\LQJ  ,QVXODWHG ODSDURVFRSLF KDQGOHV DQG WXEHV


 ,QVXODWHG PRQRSRODU DQG ELSRODUED\RQHWV


 ,QVXODWHG OHHS YDJLQDO VSHFXOXPV DQG IRUFHSV


)RU PRUH LQIRUPDWLRQ ZZZ MDFFHOO FRP


PDUN#MDFFHOO FRP


$7, )& :H 7(67 DW


YROWV '& &RQWLQXRXV WHQVLRQ


'RQ¶W EH IRROHG E\ ORZHU YROWDJH WHVWLQJ GHYLFHV


has been the highlight of my career and I am incredibly grateful to have worked alongside a tremendous team of purpose-driven individuals. Together, we have pioneered healthcare’s largest cloud-based supply chain network and built a community of tens of thousands of healthcare organizations across the globe,” said Johnson. “I’ve had the pleasure of working alongside Tina for more than two decades and admire her as a trusted advisor, customer champion and a focused and authentic leader with a passion for advancing healthcare’s value-based future. Her abil- ity to remain clear-headed and focused in the face of adversity helped steer GHX, and our customers, through the height of the COVID-19 pandemic, and will continue to make a difference in the healthcare community at large.” atanka urphy is a multi-faceted leader with a strong track record of driving global performance improvement, delivering value to customers and fostering an employee culture predicated on equity and inclusivity. Her extensive knowledge of GHX, its broad and still expanding customer community and the complex healthcare industry at large positions her to lead the company into the future.


“I am honored by the Board’s decision to entrust me as its next chief executive and I am humbled to carry on Bruce Johnson’s strong legacy of leadership, said Tina atanka urphy, incom- ing president and CEO of GHX. Read on: https://www.hpnonline.com/21281343


2211HPN_JacCellMedic.indd 1


8 November 2022 • HEALTHCARE PURCHASING NEWS • hpnonline.com 10/10/22 2:04 PM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60